What is it about?

To the best of our knowledge, this is the first study to assess resistance associated substitutions of Hepatitis C virus genotype 4a following non-response to treatment with direct acting antiviral agents.

Featured Image

Why is it important?

The study results may help in tailoring future therapy for patients with no response to DAA drugs.


This work should be extended using larger sample size and to include relapsers to multiclass drug users.

Professor Monkez M Yousif
Zagazig University

Read the Original

This page is a summary of: Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment, Infection and Drug Resistance, September 2019, Taylor & Francis, DOI: 10.2147/idr.s214735.
You can read the full text:



The following have contributed to this page